Fujifilm Holdings Corp has agreed to start new phase of medical trial in Japan of its Vaccine Avigan for the treatment of COVID-19, this news came from a reliable source on Sunday the 21st of February 2021.
The actual approval of the medicine was following due process after a health ministry panel said in December that trial data was inconclusive. The study will involve about 270 patients and Fujifilm plan is to seek approval again in October, Nikkei said.
There was no Fujifilm Team available to comment on this revelation to either be true or false.
Japanese Government has approved Avigan, known generically as favipiravir, as an emergency flu medicine. But concerns remain, as the Medicine has been shown to cause birth defects in animal studies and its effectiveness against COVID-19 has proven difficult to demonstrate.
Japan’s government has called on Fujifilm to triple national stockpiles of the drug, which has been approved for COVID-19 treatment in Russia, India and Indonesia.